XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration and License Agreements - Schedule of Deferred Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Roche | Completion of Continuing Trials      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning $ 16,645 $ 17,957  
Increase in collaboration revenue receivable   4,000  
Recognition as revenue, as the result of performance obligations satisfied (4,825) (5,312)  
Balance, Ending 11,820 16,645  
Classified as short-term 11,125    
Classified as long-term 695    
Roche | Collaboration and License Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning   18,000  
Balance, Ending 11,800    
Classified as short-term 11,100   $ 15,300
Classified as long-term 700   2,700
Bristol-Myers Squibb Company | Research Activities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning 2,082 2,448  
Increase in collaboration revenue receivable 0    
Recognition as revenue, as the result of performance obligations satisfied (1,242) (366)  
Balance, Ending 840 2,082  
Classified as short-term 840    
Classified as long-term 0    
Bristol-Myers Squibb Company | Options to License Druggable Target Lesions      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning 12,459 12,459  
Increase in collaboration revenue receivable 1,250    
Recognition as revenue, as the result of performance obligations satisfied (13,709) 0  
Balance, Ending 0 12,459  
Classified as short-term 0    
Classified as long-term 0    
Bristol-Myers Squibb Company | Options to License Undruggable Targets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning 12,447 12,447  
Increase in collaboration revenue receivable 0    
Recognition as revenue, as the result of performance obligations satisfied 0 0  
Balance, Ending 12,447 12,447  
Classified as short-term 12,447    
Classified as long-term 0    
Bristol-Myers Squibb Company | Collaboration and License Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning 26,988 27,354  
Increase in collaboration revenue receivable 1,250    
Recognition as revenue, as the result of performance obligations satisfied (14,951) (366)  
Balance, Ending 13,287 26,988  
Classified as short-term 13,287   $ 27,400
Classified as long-term 0    
Ono Pharmaceutical Company Ltd | Research Activities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Balance, Beginning 10,473 10,473  
Recognition as revenue, as the result of performance obligations satisfied (10,473) 0  
Balance, Ending $ 0 $ 10,473